Gabriel Leung
CIK 1236183 · EVP & Pres. Pharma. Business · last filed 2026-06-05
Gabriel Leung is an EVP & Pres. Pharma. Business who has filed 79 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for NVCR, was dated Jun 5, 2026. Across all open-market trades the lifetime net is −$28.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.6M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
NVCR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
LEESBURG, VA 20175
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NVCR | Director | 101,109 | $15.43 | $1.56M | -$24.16M | 44 | 2026-06-05 |
| PERNIX THERAPEUTICS HOLDINGS, INC. (PTX) Delisted | Director | — | — | — | $0 | 3 | 2018-05-23 |
| ALBANY MOLECULAR RESEARCH INC (AMRI) Delisted | Director | 31,316 | — | — | $19.2K | 9 | 2015-03-04 |
| DCTH | Director | 0 | $14.68 | $0 | $11.8K | 7 | 2014-07-09 |
| OSI PHARMACEUTICALS INC (OSIP) Delisted | EVP & Pres. Pharma. Business | 0 | — | — | -$4.15M | 16 | 2010-06-09 |
Recent Filings
79 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-05 | NVCR | Grant (A) | +11,610 | $0 | EDGAR |
| 2026-06-03 | NVCR | Sell (S) | −2,945 | -$46.4K | EDGAR |
| 2025-06-06 | NVCR | Grant (A) | +11,215 | $0 | EDGAR |
| 2025-06-04 | NVCR | Sell (S) | −999 | -$17.3K | EDGAR |
| 2024-06-06 | NVCR | Mixed | +3,089 | -$23.0K | EDGAR |
| 2023-06-09 | NVCR | Grant (A) | +3,853 | $0 | EDGAR |
| 2022-06-10 | NVCR | Grant (A) | +2,427 | $0 | EDGAR |
| 2021-08-06 | NVCR | Mixed | — | -$121.0K | EDGAR |
| 2021-07-08 | NVCR | Mixed | — | -$152.1K | EDGAR |
| 2021-06-11 | NVCR | Grant (A) | +814 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.